A detailed history of Citigroup Inc transactions in Legend Biotech Corp stock. As of the latest transaction made, Citigroup Inc holds 41,998 shares of LEGN stock, worth $1.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,998
Previous 43,480 3.41%
Holding current value
$1.38 Million
Previous $1.93 Million 6.29%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$43.55 - $59.88 $64,541 - $88,742
-1,482 Reduced 3.41%
41,998 $2.05 Million
Q2 2024

Aug 12, 2024

BUY
$39.5 - $57.22 $149,152 - $216,062
3,776 Added 9.51%
43,480 $1.93 Million
Q1 2024

May 10, 2024

SELL
$55.06 - $69.99 $1.7 Million - $2.16 Million
-30,795 Reduced 43.68%
39,704 $2.23 Million
Q4 2023

Feb 09, 2024

SELL
$57.25 - $69.74 $509,238 - $620,337
-8,895 Reduced 11.2%
70,499 $4.24 Million
Q3 2023

Nov 09, 2023

BUY
$63.16 - $76.5 $279,609 - $338,665
4,427 Added 5.91%
79,394 $5.33 Million
Q2 2023

Aug 10, 2023

SELL
$46.28 - $75.01 $375,006 - $607,806
-8,103 Reduced 9.75%
74,967 $5.17 Million
Q1 2023

May 11, 2023

BUY
$43.42 - $57.37 $315,446 - $416,793
7,265 Added 9.58%
83,070 $4.01 Million
Q4 2022

Feb 09, 2023

BUY
$38.8 - $55.46 $213,050 - $304,530
5,491 Added 7.81%
75,805 $3.78 Million
Q3 2022

Nov 10, 2022

SELL
$38.15 - $57.1 $1.68 Million - $2.52 Million
-44,082 Reduced 38.53%
70,314 $2.87 Million
Q2 2022

Aug 10, 2022

BUY
$33.54 - $55.0 $1.78 Million - $2.92 Million
53,094 Added 86.61%
114,396 $6.29 Million
Q1 2022

May 12, 2022

BUY
$31.02 - $48.18 $347,051 - $539,037
11,188 Added 22.33%
61,302 $2.23 Million
Q4 2021

Feb 10, 2022

BUY
$41.14 - $56.98 $1.42 Million - $1.97 Million
34,543 Added 221.84%
50,114 $2.34 Million
Q3 2021

Nov 10, 2021

BUY
$35.31 - $50.56 $549,812 - $787,269
15,571 New
15,571 $788,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $5.49B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.